Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) Products under Development by Stage of Development | 7 | 1 |
| Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) Products under Development by Therapy Area | 8 | 1 |
| Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) Products under Development by Indication | 9 | 1 |
| Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) Products under Development by Companies | 12 | 2 |
| Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) Products under Development by Universities/Institutes | 14 | 2 |
| Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) Therapeutics Assessment | 16 | 5 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 1 |
| Assessment by Route of Administration | 18 | 2 |
| Assessment by Molecule Type | 20 | 1 |
| Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) Companies Involved in Therapeutics Development | 21 | 3 |
| Affichem SA | 21 | 1 |
| Bristol-Myers Squibb Company | 22 | 1 |
| Vitae Pharmaceuticals, Inc. | 23 | 1 |
| Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) Drug Profiles | 24 | 5 |
| AF-122 Drug Profile | 24 | 1 |
| BMS-779788 Drug Profile | 25 | 1 |
| SR-9238 Drug Profile | 26 | 1 |
| VTP-38543 Drug Profile | 27 | 1 |
| VTP-4 Drug Profile | 28 | 1 |
| Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) Dormant Projects | 29 | 1 |
| Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) Discontinued Products | 30 | 1 |
| Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) Featured News &Press Releases | 31 | 5 |
| Dec 29, 2015: Vitae Pharmaceuticals Doses First Patients in Phase 2a Proof-of-Concept Trial of VTP-38543 in Atopic Dermatitis | 31 | 1 |
| Dec 10, 2015: Vitae Pharmaceuticals Opens Phase 2a Proof-of-Concept Trial of VTP-38543 in Atopic Dermatitis Patients | 31 | 1 |
| Apr 03, 2015: AFFICHEM announces the presentation of an oral communication at the 35th Annual Meeting of the French Society of Hematology in Paris | 32 | 1 |
| Dec 06, 2014: AFFICHEM announces the presentation of a poster at the 56th Annual Meeting of the American Society of Hematology in San Francisco | 32 | 1 |
| Dec 19, 2012: Scripps Florida Scientists Develop New Compound that Reverses Fatty Liver Disease | 32 | 1 |
| Sep 06, 2012: Vitae Pharma Announces Promising Data On Atherosclerotic Drug VTP-4 At Frontiers In Lipid Biology Conference | 33 | 1 |
| Nov 29, 2007: Exelixis To Receive Milestone Payment From Bristol-Myers Squibb For Achievement Of Liver X Receptor Agonist Development Milestone | 34 | 1 |
| Dec 06, 2005: Exelixis And Bristol-Myers Squibb Signs New Collaboration Agreement To Develop Novel Cardiovascular Disease Treatments | 34 | 2 |
| Appendix | 36 | 2 |
| Methodology | 36 | 1 |
| Coverage | 36 | 1 |
| Secondary Research | 36 | 1 |
| Primary Research | 36 | 1 |
| Expert Panel Validation | 36 | 1 |
| Contact Us | 36 | 1 |
| Disclaimer | 37 | 1 |